Mineralys Therapeutics, Inc. (MLYS) NASDAQ
30.58
+0.02(+0.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
30.58
+0.02(+0.07%)
Currency In USD
Address
150 N. Radnor Chester Rd.
Radnor, PA 19087
United States of America (the)
Phone
888-378-6240
Website
Sector
Healthcare
Industry
Biotechnology
Employees
51
First IPO Date
February 10, 2023
| Name | Title | Pay | Year Born |
| Jon Congleton | President, Chief Executive Officer & Director | 883,050 | 1963 |
| Brian Taylor Slingsby | Founder & Executive Director | 78,000 | 1977 |
| Adam Scott Levy | Chief Financial Officer & Secretary | 713,750 | 1978 |
| David Rodman | Chief Medical Officer | 742,300 | 1955 |
| Robert McKean | Senior Vice President of CMC | 0 | N/A |
| Eric J. Warren | Chief Commercial Officer | 0 | 1972 |
| Danielle Bradbury | Senior Vice President of Quality Assurance | 0 | N/A |
| Jessica Ibbitson | Executive Vice President of Operations | 0 | N/A |
| Sarah Foster | Senior Vice President of People | 0 | N/A |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | 0 | N/A |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.